B
Bull
Bull · 25%ENGN
$4.68
Szenariopreis
$1.855
+0.015 (+0.82%)Zum Schluss
Loading chart…
- High
- 1.870
- Open
- 1.840
- VWAP
- 1.84
- Vol
- 657.38K
- Mkt Cap
- —
- Low
- 1.800
- Amount
- 1.21M
- EV/EBITDA, TTM
- 0.00
enGene Therapeutics Inc., formerly enGene Holdings Inc., is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).
AI analysis of enGene Therapeutics Inc (ENGN)
holdenGene Holdings Inc is not a good buy right now due to significant financial losses and analyst downgrades. The current price is $1.825, and the company reported a net loss of $30.23 million for Q2 2026. The forward P/E ratio is 0, indicating no earnings expected in the near term, which raises concerns about its profitability and growth potential.
Bewertungskennzahlen
The current forward P/E ratio for enGene Therapeutics Inc (ENGN) is 0.00, compared to its 5-year average forward P/E of -3.05.
Alphio AI Price Scenarios for ENGN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding ENGN
Event-Zeitleiste
News
8.506-19NASDAQ.COMBiotech Sector Sees FDA Approvals and Layoffs
9.506-16NASDAQ.COMenGene Reports Wider Q2 Loss Amid Clinical Updates
9.506-15seekingalphaenGene Holdings Reports Strong Q2 Earnings and Financial Position
7.006-04PRnewswirePomerantz Investigates enGene for Securities Fraud Claims
7.006-02GlobenewswirePomerantz LLP Investigates Securities Fraud Claims Against enGene Therapeutics
ENGN FAQ — answered by Alphio AI
enGene Therapeutics Inc., formerly enGene Holdings Inc., is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA). It operates in the Healthcare sector.
enGene Holdings Inc is not a good buy right now due to significant financial losses and analyst downgrades. The current price is $1.825, and the company reported a net loss of $30.23 million for Q2 2026. The forward P/E ratio is 0, indicating no earnings expected in the near term, which raises concerns about its profitability and growth potential.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.